Zoraxel is an exciting drug because it is not a PDE-5 inhibitor like Viagra

Ongoing research into the erectile dysfunction medication Zoraxel is looking good according to Rexahn Pharmaceuticals who have been developing the product for a number of years now. The drug is now at its second phase testing stage and nothing which would exclude it from being developed and sold commercially has come up.

Zoraxel is an exciting drug because it is not a PDE-5 inhibitor like Viagra, Cialis and Levitra but is in fact a very sophisticated medication which has an effect on neurotransmitters in human brain which in turn sends signals to facilitate good erectile function.

The researchers who are using the International Index of Erectile Function scoring system to evaluate it say that the men taking part to our age between 85 and 65 did not suffer from side effects and reported a better quality of life when using the Zoraxel drug.

While the majority of male erectile dysfunction is caused by penile arterial problems which can be cured with the existing drugs Viagra, Cialis and Levitra some men suffer from a lack of sexual desire which it is hoped that Zoraxel will be able to remedy.  This drug would also be effective for the many men who have been told not to use PDE-5 inhibitors for particular medical reasons.

The chief executive officer of the company Rexahn Mr. Chang Ahn explained that the drug was a fantastic new development for the cure of erectile dysfunction which could help a certain group of men. It is particularly important for Rexahn that the results for Zoraxel are good because it has been suffering from financial losses for the last five years. Positive results for Zoraxel could turn around the finances of this company and get it back into profit.

Ukmedix News will be following the new second phase clinical trials and reporting on any outcomes.